2018 ACR/ARHP Annual Meeting coverage

Administration of a high-dose influenza vaccine results in an improved humoral immune response when given to patients with rheumatoid arthritis, suggest findings from a randomized controlled trial.

Individuals who carry the MUC5B promoter variant rs35705950 have an elevated risk for rheumatoid arthritis-associated interstitial lung disease, researchers report.

Moderate-to-high rheumatoid arthritis disease activity is associated with a twofold increased risk for associated interstitial lung disease, compared with remission or low disease activity, study findings show.

Findings from a randomized controlled trial suggest that glucocorticoid tapering is a feasible strategy for rheumatoid arthritis patients who achieve low disease activity or remission during treatment with tocilizumab and long-term glucocorticoids.

Treatment with ustekinumab may be beneficial for some patients with psoriatic arthritis and spondylitis, suggests a post-hoc subgroup analysis of the PSUMMIT 1 and 2 trials.

Findings from two phase III trials presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA, demonstrate that treatment with the JAK inhibitor peficitinib may be beneficial for patients with rheumatoid arthritis.